7.2.Pralsetinib indications published in EMA Data Sheet not funded by SNS in Spain:EMA indication #1: Pralsetinib monotherapy is indicated for treatment of adult patients with RET fusion-positive advanced NSCLC not previously treated with a RET inhibitor [55].Clinical evidence approval EMA indication #1: Phase I/II ARROW, multicenter, non-randomized, open, non-controlled, multicohort clinical trial. The gene discussed is RET; the disease is non-small cell lung carcinoma.